Altimmune (ALT) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Altimmune (ALT) over the past year, gaining 8.4% versus a loss of 33.8%. Altimmune is the larger company by market cap ($505.7 million vs $495.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | CTNM |
|---|---|---|
| Share price | $2.60 | $13.18 |
| Market cap | $505.75M | $495.85M |
| 1-day change | -2.26% | +3.53% |
| YTD return | -27.98% | +15.31% |
| 1-year return | -33.84% | +8.39% |
| 5-year return | -78.35% | — |
| EPS (TTM) | $-0.76 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $17.79 |
| 52-week low | $2.55 | $8.60 |
| Distance from 52-week high | -59.63% | -25.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +558.08% | +70.18% |
| Average volume | 4.21M | 516.85K |
| Shares outstanding | 194.52M | 32.96M |
| Employees | 57 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed ALT by 42.2 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ALT vs CTNM FAQ
Which is bigger, Altimmune or Contineum Therapeutics?
Altimmune (ALT) is larger, with a market capitalization of $505.75M compared with $495.85M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, ALT or CTNM?
CTNM returned +8.39% over the past 12 months, compared with -33.84% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.